ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach
Targeting GI Diseases
Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.
